A Phase 1 interventional study of Nalmefene Hydrochloride in Opioid Overdose, sponsored by Opiant Pharmaceuticals Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-05.
Sponsored by Opiant Pharmaceuticals Inc (part of Indivior Pharmaceuticals, Inc.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Opiate Overdose with a site in United States — 8 open to participants now, 15 under way, none of them phase 3. Opiate Overdose · United States.
Among the 56 studies in Opiate Overdose with a site in United States, this one is the 37th largest by enrollment of the 44 interventional ones that give a count, is one of 10 that started in 2021, is one of 6 in phase 1, and was the 28th registered.
70 studies on the registry are indexed under Opiate Overdose; 11 are open to participants now.
Browse Opiate Overdose studies →8 of the 56 studies in Opiate Overdose with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 19+
University of Illinois at Chicago · Sites in United States
Ages 18+ · Healthy volunteers
Drexel University · Sites in United States
Ages 18+ · Healthy volunteers
University of Washington · Sites in United States
Ages 18+
Hartford Hospital · Sites in United States
Ages 21–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Opiate Overdose studies recruiting now, 6 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 184 across 48 interventional studies indexed under Opiate Overdose.
Median enrollment 184 across the 44 interventional studies, 106 across the 12 observational. Of the 35 that completed or were terminated, 15 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 56 have an industry lead sponsor. The 10 most frequent:
This study is registered under Opiant Pharmaceuticals Inc, one of the names counted as Indivior Pharmaceuticals, Inc.. Under that name alone:
Opiant Pharmaceuticals Inc is the lead sponsor of 3 studies on the registry; none are open to participants now.
Indivior Pharmaceuticals, Inc. has 1 study filed under Opiate Overdose — fewer than ten, so there is no comparison to draw.
1 of the studies in Opiate Overdose with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05713695University of Massachusetts, WorcesterSupporting Treatment Access and Recovery Through Linkage and Support | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 56 studies in Opiate Overdose with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to compare the pharmacokinetics (how the body absorbs, breaks down and eliminates drug from your body) of nalmefene when given as a single dose intranasally (IN;into the nose), as a single dose in each nostril and as two doses in one nostrils; and to evaluate the safety and tolerability of nalmefene IN.
Open-label, randomized, 3-period, 3-treatment, 6-sequence, ranodmised crossover study in 24 healthy volunteers. Subjects will be assigned to each of the 6 possible sequences. Each subject will receive 3 intranasal (IN) nalmefene doses:
There will be a 6 day washout period between doses. Screening can occur up to 28 days before admission, subjects will then stay in the inpatient facility for 16 days to complete the treatment phase of the study and will be discharged following completion of the discharge procedures at the end of the last period. Subjects will be called 3 to 5 days after discharge to inquire concerning Adverse Events (AEs) and concomitant medications since discharge.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
On screening and admission, the following standards had to be met before dosing and were permitted to be repeated once:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 mg IN Nalmefene Hydrochloride dose (one 0.1 mL spray of a 30 mg/mL solution in one nostril)
Drug: Nalmefene Hydrochloride
6 mg IN Nalmefene Hydrochloride dose (two 0.1 mL sprays of a 30 mg/mL solution in one nostril)
Drug: Nalmefene Hydrochloride
6 mg IN Nalmefene Hydrochloride dose (one 0.1 mL spray of a 30 mg/mL solution in each nostril)
Drug: Nalmefene Hydrochloride
30 mg/mL solution
Maximum Plasma Concentration (Cmax)
Maximum concentration of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
Time frame: 48 hours
Time to Maximum Plasma Concentration (Tmax)
Time to maximum concentration of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
Time frame: 48 hours
Area Under the Curve (AUC)
Area under the curve of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
Time frame: 48 hours
Half-life (t1/2)
Half life of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
Time frame: 48 hours
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 3 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 3 | 4 | 4 | 4 |
| Completed | 4 | 4 | 3 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 3 | 4 | 4 | 4 |
| Completed | 4 | 4 | 3 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 3 | 4 | 4 | 4 |
| Completed | 4 | 4 | 3 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 3 | 4 | 4 | 4 |
| Completed | 4 | 4 | 3 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Maximum concentration of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
| ng/ml | Intranasal Nalmefene 1 Spray in 1 Nostril | Intranasal Nalmefene 2 Sprays in 1 Nostril | Intranasal Nalmefene 1 Spray in Each Nostril |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) | 10.8 ± 4.87 | 18.9 ± 11.2 | 22.2 ± 13.5 |
Time to maximum concentration of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
| hours | Intranasal Nalmefene 1 Spray in 1 Nostril | Intranasal Nalmefene 2 Sprays in 1 Nostril | Intranasal Nalmefene 1 Spray in Each Nostril |
|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) | 0.267 (0.167 to 2.03) | 0.25 (0.117 to 3) | 0.25 (0.117 to 2.03) |
Area under the curve of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
| AUCinf (ng·h/mL) | Intranasal Nalmefene 1 Spray in 1 Nostril | Intranasal Nalmefene 2 Sprays in 1 Nostril | Intranasal Nalmefene 1 Spray in Each Nostril |
|---|---|---|---|
| Area Under the Curve (AUC) | 46.8 ± 10.1 | 85.7 ± 18.7 | 89.5 ± 17.0 |
Half life of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
| hour | Intranasal Nalmefene 1 Spray in 1 Nostril | Intranasal Nalmefene 2 Sprays in 1 Nostril | Intranasal Nalmefene 1 Spray in Each Nostril |
|---|---|---|---|
| Half-life (t1/2) | 11.4 ± 2.51 | 11.3 ± 1.86 | 11.3 ± 1.87 |
Collected over Subjects were collected AE from baseline to day 15 with a +3 to 5 day follow-up. During the 15 days in clinic they received one of the three doing regimens on day 1, 7 and 13.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intranasal Nalmefene 1 Spray in 1 Nostril | 0/23 (0%) | 0/23 (0%) | 9/23 (39.1%) |
| Intranasal Nalmefene 2 Sprays in 1 Nostril | 0/24 (0%) | 0/24 (0%) | 16/24 (66.7%) |
| Intranasal Nalmefene 1 Spray in Each Nostril | 0/23 (0%) | 0/23 (0%) | 12/23 (52.2%) |
| Event | Intranasal Nalmefene 1 Spray in 1 Nostril | Intranasal Nalmefene 2 Sprays in 1 Nostril | Intranasal Nalmefene 1 Spray in Each Nostril |
|---|---|---|---|
| RhinalgiaRespiratory, thoracic and mediastinal disorders | 3/23 | 6/24 | 2/23 |
| NauseaGastrointestinal disorders | 1/23 | 1/24 | 5/23 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 1/23 | 4/24 | 1/23 |
| Nasal discomfortRespiratory, thoracic and mediastinal disorders | 1/23 | 3/24 | 3/23 |
| HeadacheNervous system disorders | 3/23 | 0/24 | 1/23 |
| Vessel puncture site painGeneral disorders | 0/23 | 2/24 | 0/23 |
| Age, Continuous(years) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 27.8 ± 5.91 | 32.0 ± 9.20 | 35.0 ± 8.29 | 37.5 ± 12.40 | 28.0 ± 6.73 | 27.0 ± 6.06 | 31.2 ± 8.47 |
| Sex: Female, Male(Participants) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 3 | 3 | 1 | 3 | 3 | 15 |
| Male | 2 | 1 | 1 | 3 | 1 | 1 | 9 |
| Race (NIH/OMB)(Participants) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 0 | 1 | 3 | 2 | 10 |
| White | 2 | 2 | 3 | 2 | 1 | 2 | 12 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Total |
|---|---|---|---|---|---|---|---|
| United States | 4 | 4 | 4 | 4 | 4 | 4 | 24 |
| BMI(kg/m2) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 26.28 ± 4.853 | 25.80 ± 2.226 | 24.30 ± 2.426 | 23.18 ± 4.921 | 23.00 ± 2.362 | 24.58 ± 3.222 | 24.52 ± 3.357 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Nov 2021, 2 months.
Results were first posted in Aug 2024, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalmefene